4-(benzylthio)-3-methyl-1-butene | 172295-00-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(benzylthio)-3-methyl-1-butene
• 英文别名: benzyl (2-methylbut-3-enyl) sulfide；benzyl(2-methylbut-3-en-1-yl)sulfane；2-Methylbut-3-enylsulfanylmethylbenzene
• CAS: 172295-00-0
• 化学式: C₁₂H₁₆S
• 分子量: 192.325
• InChiKey: KIEOOTQAQQDCJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(benzylthio)-3-methyl-1-butene 在 盐酸 、 4-二甲氨基吡啶 、 亚碘酰苯 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 32.5h， 生成 (S)-6'-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-N-((2-methylbut-3-en-1-yl)sulfonyl)-3',4,4',5-tetrahydro-2H,2'H-spiro[benzo[b][1,4]oxazepine-3,1'-naphthalene]-7-carboxamide
  参考文献：
  名称：

  [EN] TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN
  [FR] DÉRIVÉS DU TÉTRAHYDRONAPHTALÈNE INHIBANT LA PROTÉINE MCL-1

  摘要：

  本文提供了髓样细胞白血病1蛋白（Mcl-1）抑制剂，其制备方法，相关的药物组合物，以及使用这些抑制剂的方法。例如，本文提供了化合物I的公式（I），及其药用盐和含有这些化合物的药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或症状。

  公开号：

  WO2016033486A1
• 作为产物：
  描述：

  1-(phenylthio)-2-butenes 在 cesium fluoride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 4-(benzylthio)-3-methyl-1-butene
  参考文献：
  名称：

  Comparison of the Reaction of Benzylammonium N-Methylides with That of Benzylsulfonium S-Methylides.

  摘要：

  通过氟离子诱导 S-苄基-S-[(三甲基硅基)甲基](烷-2-烯基)锍盐 4S 和 S-苄基-S-[(三甲基硅基)甲基](4-取代苄基)锍盐 7S 的脱硅作用，生成了烯丙基锍 S-甲基化物 8S 和二苄基锍 S-甲基化物 18S、并将异构化产物与相应的 N-甲基化物的异构化产物进行比较。S 型甲基化物 8S 选择性地向烯丙基发生重排（图 2 中的路径 a），而 N 型甲基化物 8N 则竞争性地向苄基发生重排（路径 b）。S 型甲基化物 18S 异构化为 S 型苄基化物 19S 和 20S 时，会竞争性地向苄基发生重排（图 3 中的路径 a 和 b），而 N 型甲基化物 18N 则不会发生异构化。

  DOI：

  10.1248/cpb.47.267

文献信息

• COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
  申请人：AMGEN INC.

  公开号：US20160068545A1

  公开（公告）日：2016-03-10

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

  本文提供了髓系细胞白血病1蛋白（Mcl-1）抑制剂、其制备方法、相关药物组合物以及使用方法。例如，本文提供了I式化合物及其药用可接受盐和药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或病情。
• Compounds that inhibit Mcl-1 protein
  申请人：AMGEN INC.

  公开号：US10100063B2

  公开（公告）日：2018-10-16

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

  本文提供了髓细胞白血病 1 蛋白（Mcl-1）抑制剂、其制备方法、相关药物组合物以及使用方法。例如，本文提供了式 I 的化合物、 及其药学上可接受的盐类，以及含有这些化合物的药物组合物。本文提供的化合物和组合物可用于治疗癌症等疾病或病症。
• Compounds that inhibit MCL-1 protein
  申请人：AMGEN INC.

  公开号：US10836779B2

  公开（公告）日：2020-11-17

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

  本文提供了髓细胞白血病 1 蛋白（Mcl-1）抑制剂、其制备方法、相关药物组合物以及使用方法。例如，本文提供了式 I 的化合物、 及其药学上可接受的盐类，以及含有这些化合物的药物组合物。本文提供的化合物和组合物可用于治疗癌症等疾病或病症。
• Regiochemical and stereochemical studies on halocyclization reactions of unsaturated sulfides
  作者：Xiao-Feng Ren、Edward Turos、Charles H. Lake、Melvyn Rowen Churchill

  DOI：10.1021/jo00125a038

  日期：1995.10

  The regiochemistry and stereochemistry for the halocyclization reactions of unsaturated benzyl sulfides have been examined as a function of tether length, type of unsaturation (carbon-carbon double bond versus carbon-carbon triple bond), substituents, and halogenating agent. Alkenyl sulfides were found to react with iodine or bromine at room temperature to give five-membered ring cycloadducts exclusively over those having four-membered rings, while for larger systems, six-membered ring products are formed preferentially over their five-membered ring isomers and exclusively over the seven-membered ring adducts. The endo- versus exo-regioselectivity of these alkenyl sulfide ring closures most likely reflects the difference in thermodynamic stabilities of the beta-halo sulfide cycloadducts, which are able to equilibrate via a common episulfonium intermediate. The efficiency of the cyclization process markedly drops off for these alkenyl sulfides as the tether length increases beyond four intervening carbon centers. Thus, while the halogenations of 3-butenyl sulfides and 4-pentenyl sulfides give high yields of cycloadducts, those of 5-hexenyl sulfides afford only small amounts of cyclized products and large quantities of acyclic dibromides. Conversely the reactions of acetylenic sulfides with iodine give uniformly high yields and regiochemical control regardless of the tether length. Thus, 3-butynyl and 4-pentynyl sulfides cyclize cleanly to the five-membered ring while 5-hexynyl sulfides give exclusively the six-membered ring, The products arising from these alkynyl sulfide ring closures are believed to be formed under kinetic control. The methodology has been applied to the synthesis of unusual bicyclic beta-lactams related to the penicillin family of antibiotics.
• TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN
  申请人：Amgen Inc.

  公开号：EP3186259A1

  公开（公告）日：2017-07-05